Patents Examined by Selam Berhane
-
Patent number: 11926660Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of Aß plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.Type: GrantFiled: August 24, 2021Date of Patent: March 12, 2024Assignee: Washington UniversityInventors: David Holtzman, Hong Jiang, Thu Nga Bien-Ly, Mark S. Dennis, Jing Guo, Adam P. Silverman, Ryan J. Watts, Yin Zhang
-
Patent number: 11926675Abstract: Disclosed is an antibody that specifically binds CD24, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD24 signaling using the antibody or antigen binding portion thereof are also provided.Type: GrantFiled: March 3, 2022Date of Patent: March 12, 2024Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.Inventors: Wenzhi Tian, Song Li, Dianze Chen, Huiqin Guo
-
Patent number: 11912770Abstract: Provided are a single-domain antibody against human programmed death-ligand 1 (PD-L1) and application thereof. The PD-L1 binding molecule of the present invention can be used for treating and/or preventing, or diagnosing PD-L1 related diseases such as tumors.Type: GrantFiled: February 14, 2019Date of Patent: February 27, 2024Assignee: SHANGHAI NOVAMAB BIOPHARMACEUTICALS CO., LTD.Inventors: Yakun Wan, Min Zhu, Xiaoning Shen, Junwei Gai
-
Patent number: 11912781Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.Type: GrantFiled: January 13, 2022Date of Patent: February 27, 2024Assignee: Visterra, Inc.Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver, Lauren Olinski
-
Patent number: 11897949Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.Type: GrantFiled: May 28, 2021Date of Patent: February 13, 2024Assignee: MedImmune LimitedInventors: Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
-
Patent number: 11858974Abstract: Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural ?-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.Type: GrantFiled: May 22, 2018Date of Patent: January 2, 2024Assignee: RESQ BIOTECHInventor: Georgios Skretas
-
Patent number: 11820811Abstract: A nanobody and its application based on SARS-CoV-2 S protein are provided, and the present disclosure relates to biomedical technology. The present disclosure chooses the Spike S1+S2 ECD of SARS-CoV-2 as a target, and screens the nanobody against of SARS-CoV-2 by using a nanobody library. After an ELISA test, the Spike S1+S2 ECD target of SARS-CoV-2 can be specifically identified while a SPIKE RBD target is identified, and a binding signal is relatively strong. The corresponding nanobody sequence is constructed into a prokaryotic expression vector for expression and purification to express the target nanobody successfully. After the purification, the purity is greater than 90%. The ELISA test of VHH nanobody showed that the purified nanobody has higher affinity to the two targets.Type: GrantFiled: July 9, 2021Date of Patent: November 21, 2023Assignee: Shihezi UniversityInventors: Chuangfu Chen, Peng Wu, Chencheng Xiao, Chengyao Li, Yong Wang, Zhen Wang
-
Patent number: 11753477Abstract: Provided herein are a preparation method and use of an anti-MET-and-RON bispecific antibody and an antibody-drug conjugate thereof. The anti-MET-and-RON bispecific antibody includes an anti-MET antibody fragment and an anti-RON antibody fragment which are linked to each other through a specific chemical “knobs-into-holes” structure.Type: GrantFiled: February 10, 2021Date of Patent: September 12, 2023Assignee: PCM TARGETECH, LLCInventors: Ming-Hai Wang, Hang-Ping Yao
-
Patent number: 11661448Abstract: A nanobody and its application based on SARS-CoV-2 S protein S1 subunit are provided, and the present disclosure relates to biomedical technology. The present disclosure chooses the Spike RBD of SARS-CoV-2 as a target, and screens the nanobody targeting SARS-CoV-2 by using a nanobody library. After an ELISA test, the Spike RBD target of SARS-CoV-2 can be specifically identification while a SPIKE S1+S2 ECD target is identification, and a binding signal is relatively strong. The corresponding nanobody sequence is constructed into a prokaryotic expression vector for expression and purification to express the target nanobody successfully. After purification, the purity is greater than 90%. The ELISA test of VHH nanobody showed that the purified nanobody has higher affinity to the two targets.Type: GrantFiled: July 9, 2021Date of Patent: May 30, 2023Assignee: Shihezi UniversityInventors: Chuangfu Chen, Peng Wu, Chencheng Xiao, Chengyao Li, Yong Wang, Zhen Wang